Atlantic's 15min chart shows KDJ Golden Cross, Bullish Marubozu pattern.

According to Atlantic's 15-minute chart, a golden cross has occurred, accompanied by a bullish marubozu candlestick formation on October 8, 2025, at 15:45. This indicates a shift in the momentum of the stock price towards an upward trajectory, suggesting that the stock has the potential to further appreciate. The current market conditions are characterized by strong buying activity, which is likely to continue to drive bullish momentum.

Invivyd (IVVD), a clinical-stage biopharmaceutical company focused on monoclonal antibody therapies, has been making significant strides in its efforts to combat evolving viral threats like COVID-19. According to Atlantic's 15-minute chart, a golden cross occurred on October 8, 2025, at 15:45, accompanied by a bullish marubozu candlestick formation. This technical indicator suggests a shift in the momentum of the stock price towards an upward trajectory, indicating potential for further appreciation.

The company's recent announcements underscore its commitment to innovation and growth. Invivyd has received U.S. FDA clearance for its Investigational New Drug (IND) application and alignment on the REVOLUTION clinical program for VYD2311, a vaccine-alternative monoclonal antibody to prevent COVID-19. The company plans to initiate two trials, DECLARATION and LIBERTY, with top-line data anticipated in mid-2026. The funding for these trials is secured through a recent capital raise.

Additionally, Invivyd has appointed Dr. Paul B. Bolno, M.D., to its Board of Directors and Compensation Committee, bringing extensive experience in pipeline development and technological platforms. The appointment comes as Invivyd focuses on developing solutions for viral infectious diseases, particularly in the areas of COVID-19 prevention and treatment.

The company's pipeline expansion includes RSV and measles candidates, with updates expected in Q3 and Q4 2025. Invivyd's Q2 2025 financial results highlighted a net product revenue of $11.8 million for PEMGARDA®, representing 413% year-over-year growth. The company also reported positive Phase 1/2 data for VYD2311, demonstrating favorable safety and a 76-day half-life for intramuscular administration.

Invivyd's strategic initiatives and recent milestones have positioned the company as a key player in infectious disease innovation. The strong buying activity and bullish momentum, as indicated by the golden cross and marubozu candlestick formation, suggest that Invivyd's stock has the potential to continue its upward trajectory.